Royalty Pharma PLC Class A

RPRX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
<XLOCK|>SZ!LOCK|>#Fc>@l#

Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts

Royalty Pharma delivered 10% growth in portfolio receipts during the first quarter, leading management to lift guidance for their revenue proxy by about 100 basis points. Adjusted EBITDA increased 21% and the firm announced capital deployment of $528 million in the quarter.

Sponsor Center